{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:15:12Z","timestamp":1707524112832},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,23]]},"DOI":"10.7759\/cureus.8786","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T16:44:56Z","timestamp":1592930696000},"source":"Crossref","is-referenced-by-count":0,"title":["Checkpoint Inhibitor in a Melanoma Patient With Polyendocrinopathy and Gangrenous Gall Bladder With a Mass"],"prefix":"10.7759","author":[{"given":"Nayson L","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soujanya","family":"Sodavarapu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukhmine","family":"Nedopil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikita","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6109(02)00162-7","article-title":"Immunotherapy of malignant melanoma","volume":"83","author":"Kadison AS","year":"2003","unstructured":"Kadison AS, Morton DL. Immunotherapy of malignant melanoma. Surg Clin North Am. 2003, 83:343-370. 10.1016\/S0039-6109(02)00162-7","journal-title":"Surg Clin North Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.06.012","article-title":"Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma","volume":"40","author":"McDermott D","year":"2014","unstructured":"McDermott D, Lebb\u00e9 C, Hodi FS, et al.. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 2014, 40:1056-1064. 10.1016\/j.ctrv.2014.06.012","journal-title":"Cancer Treat Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.3700","article-title":"Role of anti-PD-1 antibodies in advanced melanoma: the era of immunotherapy","volume":"10","author":"Sahni S","year":"2018","unstructured":"Sahni S, Valecha G, Sahni A. Role of anti-PD-1 antibodies in advanced melanoma: the era of immunotherapy. Cureus. 2018, 10:e3700. 10.7759\/cureus.3700","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai Y","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002, 99:12293-12297. 10.1073\/pnas.192461099","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011936","article-title":"Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer. A meta-analysis of randomized controlled trials","volume":"97","author":"Khan M","year":"2018","unstructured":"Khan M, Lin J, Liao G, et al.. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer. A meta-analysis of randomized controlled trials. Medicine. 2018, 97:e11936. 10.1097\/MD.0000000000011936","journal-title":"Medicine"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S53163","article-title":"Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway","volume":"7","author":"Momtaz P","year":"2014","unstructured":"Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med. 2014, 7:357-365. 10.2147\/PGPM.S53163","journal-title":"Pharmgenomics Pers Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger R","year":"2008","unstructured":"Berger R, Rotem-Yehudar R, Slama G, et al.. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008, 14:3044-3051. 10.1158\/1078-0432.CCR-07-4079","journal-title":"Clin Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"29","author":"Hamid O","year":"2018","unstructured":"Hamid O, Robert C, Daud A, et al.. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2018, 29:134-144. 10.1056\/NEJMoa1305133","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE- 002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas A","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, et al.. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE- 002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015, 16:908-918. 10.1016\/S1470-2045(15)00083-2","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al.. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015, 372:2521-2532. 10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma","volume":"116","author":"Hino R","year":"2010","unstructured":"Hino R, Kabashima K, Kato Y, et al.. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010, 116:1757-1766. 10.1002\/cncr.24899","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel SP","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015, 14:847-856. 10.1158\/1535-7163.MCT-14-0983","journal-title":"Mol Cancer Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/apjon.apjon_3_19","article-title":"Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines","volume":"6","author":"Trinh S","year":"2019","unstructured":"Trinh S, Le A, Gowani S, La-Beck NM. Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines. Asia Pac J Oncol Nurs. 2019, 6:154-160. 10.4103\/apjon.apjon_3_19","journal-title":"Asia Pac J Oncol Nurs"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr3750","article-title":"Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study","volume":"11","author":"Bajwa R","year":"2019","unstructured":"Bajwa R, Cheema A, Khan T, et al.. Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study. J Clin Med Res. 2019, 11:225-236. 10.14740\/jocmr3750","journal-title":"J Clin Med Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2062-3","article-title":"Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report","volume":"67","author":"Kashima J","year":"2018","unstructured":"Kashima J, Okuma Y, Shimizuguchi R, Chiba K. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother. 2018, 67:61-65. 10.1007\/s00262-017-2062-3","journal-title":"Cancer Immunol Immunother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.10.007","article-title":"Late-onset cholecystitis with cholangitis after avelumab treatment in non-small cell lung cancer","volume":"13","author":"Cho JH","year":"2018","unstructured":"Cho JH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Late-onset cholecystitis with cholangitis after avelumab treatment in non-small cell lung cancer. J Thorac Oncol. 2018, 13:34-36. 10.1016\/j.jtho.2017.10.007","journal-title":"J Thorac Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma","volume":"1","author":"Paepegaey AC","year":"2017","unstructured":"Paepegaey AC, Lheure C, Ratour C, et al.. Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma. J Endocr Soc. 2017, 1:646-649. 10.1210\/js.2017-00170","journal-title":"J Endocr Soc"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0146","article-title":"Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis","volume":"2","author":"Min L","year":"2014","unstructured":"Min L, Hodi FS. Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res. 2014, 2:15-18. 10.1158\/2326-6066.CIR-13-0146","journal-title":"Cancer Immunol Res"},{"key":"ref19","article-title":"Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy","volume":"34","author":"Kust D","year":"2014","unstructured":"Kust D, Prpi\u0107 M, Murgi\u0107 J, et al.. Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy. Anticancer Res. 2014, 34:3177-3184.","journal-title":"Anticancer Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.118","article-title":"Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis","volume":"11","author":"Abdel-Rahman O","year":"2015","unstructured":"Abdel-Rahman O, ElHalawani H, Fouad M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol. 2015, 11:2471-2484. 10.2217\/fon.15.118","journal-title":"Future Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/34719-checkpoint-inhibitor-in-a-melanoma-patient-with-polyendocrinopathy-and-gangrenous-gall-bladder-with-a-mass","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:26:38Z","timestamp":1707506798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/34719-checkpoint-inhibitor-in-a-melanoma-patient-with-polyendocrinopathy-and-gangrenous-gall-bladder-with-a-mass"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.8786","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,23]]}}}